



Press Release

Zalicus Selected to Join the NASDAQ Biotechnology Index

CAMBRIDGE, Mass., May 17, 2011 (BUSINESS WIRE) --

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced that it has been selected to join the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to market open on Monday, May 23, 2011.

About NASDAQ Biotechnology Index

The NASDAQ Biotechnology Index, which was launched in 1993, includes pharmaceutical and biotechnology companies as classified according to the Industry Classification Benchmark. The Index is ranked on a semi-annual basis and serves as the basis for the iShares NASDAQ Biotechnology Index Fund (IBB). All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, and meet minimum market value and share volume requirements among other criteria. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit <https://indexes.nasdaqomx.com/>.

About Zalicus

Zalicus Inc. (Nasdaq: ZLCS) is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Zalicus applies its selective ion-channel modulation platform and its combination high throughput screening capabilities to discover innovative therapeutics for itself and its collaborators in the areas of pain, inflammation, oncology and infectious disease. To learn more about Zalicus, please visit www.zalicus.com.

Forward-Looking Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its product candidates, their potential and the plans for their clinical development, the Zalicus selective ion channel modulation technology, and related preclinical product candidates, Zalicus's combination drug discovery technology, cHTS, and its other business plans. These forward-looking statements about future expectations, plans, objectives and prospects of Zalicus may be identified by words like "believe," "expect," "may," "will," "should," "seek," "plan" or "could" and similar expressions and involve significant risks, uncertainties and assumptions, including risks related to the sale and marketing of Exalgo by Covidien, risks related to the development and regulatory approval of Zalicus's product candidates, including risks relating to formulation and clinical development of Synavive and Prednisporin, the unproven nature of the Zalicus drug discovery technologies, the ability of Covidien and Fovea/Sanofi Aventis to perform their obligations under their agreements with Zalicus, the ability of the Company or its collaboration partners to initiate and successfully complete clinical trials of its product candidates, the Company's ability to obtain additional financing or funding for its research and development and those other risks that can be found in the "Risk Factors" section of Zalicus's annual report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Zalicus periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Zalicus contemplated by these forward-looking statements. These forward-looking statements reflect management's current views and Zalicus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

(c) 2011 Zalicus Inc. All rights reserved.

SOURCE: Zalicus Inc.

Zalicus Inc.
Justin Renz, 617-301-7575
Senior Vice President, CFO
JRenz@zalicus.com
or
Zalicus Inc.
Gina Nugent, 617-460-3579
IRO
gnugent@zalicus.com